ÁNGEL
PONFERRADA DÍAZ
Profesor asociado
Hospital Universitario Arnau de Vilanova
Lleida, EspañaPublicacions en col·laboració amb investigadors/es de Hospital Universitario Arnau de Vilanova (8)
2024
-
Comparative Study of the Effectiveness of Vedolizumab Versus Ustekinumab After Anti-TNF Failure in Crohn's Disease (Versus-CD): Data from the ENEIDA Registry
Journal of Crohn's & colitis, Vol. 18, Núm. 1, pp. 65-74
-
HIV infection is associated with a less aggressive phenotype of inflammatory bowel disease. A multicenter study of the ENEIDA registry.
American Journal of Gastroenterology
-
Long-term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study
Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 10, pp. 1325-1338
-
Psoriasis induced by antiTNF therapy in inflammatory bowel disease: Therapeutic management and evolution of both diseases in a nationwide cohort study
Digestive and Liver Disease, Vol. 56, Núm. 12, pp. 2060-2068
-
Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA
Clinical Gastroenterology and Hepatology, Vol. 22, Núm. 11, pp. 2280-2290
2022
-
Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study (J. Clin. Med., (2021), 10, (2885), 10.3390/jcm10132885)
Journal of Clinical Medicine
-
Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry
Journal of Clinical Medicine, Vol. 11, Núm. 2
-
Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)
Journal of Clinical Medicine, Vol. 11, Núm. 24